20:50:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-21 Ordinarie utdelning HLUN A 0.70 DKK
2024-03-21 Ordinarie utdelning HLUN B 0.70 DKK
2024-03-20 Årsstämma 2024
2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-16 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning HLUN A 0.58 DKK
2023-03-22 Ordinarie utdelning HLUN B 0.58 DKK
2023-03-21 Årsstämma 2023
2023-02-08 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Split HLUN B 1:5
2022-06-08 Extra Bolagsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-24 Ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 Årsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-24 Ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-03-25 Ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-14 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-27 Ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-31 Ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-11 Kvartalsrapport 2016-Q1
2016-04-01 Ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 Årsstämma 2016
2016-02-10 Bokslutskommuniké 2015
2015-11-04 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-03-26 Ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-03-27 Ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 Årsstämma 2014
2014-02-06 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-07 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-22 Ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-08 Kvartalsrapport 2012-Q2
2012-05-02 Kvartalsrapport 2012-Q1
2012-03-30 Ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-11-09 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-04 Kvartalsrapport 2011-Q1
2011-03-31 Ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 Årsstämma 2011
2010-04-21 Ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 Ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2021-05-03 07:34:50

A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Patients included in the study had a primary diagnosis of MDD and a diagnosis of comorbid GAD. These patients represent one of the largest subpopulations of patients with MDD.

H. Lundbeck A/S (Lundbeck) announces positive data showing that Trintellix/Brintellix[®] (vortioxetine) helps people living with Major Depressive Disorder and Generalized Anxiety Disorder as a co-morbidity. The study, which is called RECONNECT, was carried out from the end of 2019 and finished March 2021.

A significant improvement in symptoms of depression as measured by Montgomery-Åsberg Depression Rating Scale (MADRS) was observed with a decrease of 16.85 points from baseline. The MADRS total score has a range of 0-60, with higher scores indicating greater severity, and a decrease of 16.85 is considered clinically meaningful. There was also a significant improvement in anxiety symptoms, with a decrease of 16.05 points from baseline as measured by the Hamilton Anxiety Rating Scale (HAM-A). HAM-A has a range from 0-56, with higher scores indicating greater severity, and a decrease of 16.05 is seen as a clinically meaningful improvement.

"We are very pleased to be able to share such positive data on the effects of vortioxetine in people diagnosed with both MDD and GAD, a highly comorbid condition. The observed improvements on functional readouts following vortioxetine treatment are particularly encouraging, since patients with MDD and comorbid GAD are well-recognized to have poor overall functioning, including patients' social, family and work life," says Johan Luthman, Executive Vice President, Research and Development at Lundbeck.

Improvement in depressive and anxiety symptoms in the study population was strongly and significantly correlated with improvement in patients overall functioning, as measured by the clinician-rated Functioning Assessment Short Test (FAST), and health-related quality of life, as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire long form (Q-LES-Q). Safety and tolerability data reported in the study were consistent with data from the pivotal development program of vortioxetine, confirming the tolerability profile of the compound.

In total, 100 patients were enrolled in the study. The patients had a primary diagnosis of MDD and comorbid diagnosis of GAD (made prior to their current event depressive episode).
At study entry the patients were severely depressed (average MADRS total score at baseline 30 points) and anxious (average HAM-A total score at baseline 29 points). Patients were treated open-label with flexible doses of 10 and 20 mg vortioxetine. A forced up-titration to 20 mg vortioxetine was scheduled after 1 week of treatment with 10 mg. The study was conducted in France, Spain, Italy, South Korea, and Poland. Seventy-seven percent of the patients had already failed another antidepressant before enrolling in the study.

Patients with MDD and comorbid GAD is a patient population that is more difficult to treat than patients with a singular diagnosis of MDD or GAD.[i] This means longer treatment duration, higher risk of withdrawal from treatment, and poorer remission rates. Patients who have depression and comorbid anxiety also have higher severity of illness, higher chronicity, and significantly greater impairment in work functioning, psychosocial functioning, and quality of life than patients not suffering from comorbidity[ii].

The results of the study will be presented at ECNP's (The European College of Neuropsychopharmacology) yearly congress in October in Lisbon this year and is intended to be published in a peer-reviewed scientific journal during 2021/2022.

Contacts

Mikkel Ballegaard Thomas Mikkel Mortensen
Pedersen
Media Relations Media Relations Lead, Corp. Communication
Specialist, Corp.
Communication
mbap@lundbeck.com thmr@lundbeck.com
+45 30 83 20 44 +45 30 83 30 24
 

About RECONNECT
The study was an 8-week interventional, open-label effectiveness study of flexible doses of vortioxetine (10 and 20 mg) with a primary objective to investigate the effect on depressive symptoms in patients with MDD comorbid with GAD. The primary outcome was change from baseline to week 8 in MADRS total score. Key secondary endpoints in the study included change from baseline to week 8 in HAM-A total score, Functioning Assessment Short Test (FAST), and Q-LES-Q.  

About vortioxetine
The mechanism of the antidepressant effect of vortioxetine is not fully understood. It is an inhibitor of serotonin (5-HT) reuptake and that is thought to be a mechanism of its action. It is also an agonist at 5-HT\1A\ receptors, a partial agonist at 5-HT\1B\ receptors and an antagonist at 5-HT\3\, 5-HT\1D\ and 5-HT\7\ receptors. The contribution of each of these activities to vortioxetine's antidepressant effect has not been established. Vortioxetine is considered to be the first and only compound with this combination of pharmacodynamic activity. The clinical relevance of this is unknown. Vortioxetine was discovered by Lundbeck researchers in Copenhagen, Denmark. Depending on the market, vortioxetine is known as Trintellix[®] or Brintellix[®].

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Millions of people worldwide live with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.

Our approximately 5,600 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and the US, and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.7 billion in 2020 (EUR 2.4 billion; USD 2.7 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck (https://twitter.com/lundbeck) andvia LinkedIn (https://www.linkedin.com/company/lundbeck/).

 

[i] Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999; 156: 1915-1923.

[ii] Hirschfeld RM. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Prim Care Companion J Clin Psychiatry. 2001; Dec;3(6): 244-254.